These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32949047)

  • 21. Phosphorylated NF-κB subunit p65 aggregates in granulovacuolar degeneration and neurites in neurodegenerative diseases with tauopathy.
    Yamaguchi Y; Ayaki T; Li F; Tsujimura A; Kamada M; Ito H; Maki T; Sawamoto N; Urushitani M; Takahashi R
    Neurosci Lett; 2019 Jun; 704():229-235. PubMed ID: 30946927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes.
    Tomé SO; Vandenberghe R; Ospitalieri S; Van Schoor E; Tousseyn T; Otto M; von Arnim CAF; Thal DR
    Acta Neuropathol Commun; 2020 Apr; 8(1):61. PubMed ID: 32349792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion.
    Junttila A; Kuvaja M; Hartikainen P; Siloaho M; Helisalmi S; Moilanen V; Kiviharju A; Jansson L; Tienari PJ; Remes AM; Herukka SK
    Dement Geriatr Cogn Dis Extra; 2016; 6(1):142-9. PubMed ID: 27195002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characteristics of FTLD-TDP showing corticospinal tract degeneration but lacking lower motor neuron loss.
    Kobayashi Z; Tsuchiya K; Arai T; Yokota O; Yoshida M; Shimomura Y; Kondo H; Haga C; Asaoka T; Onaya M; Ishizu H; Akiyama H; Mizusawa H
    J Neurol Sci; 2010 Nov; 298(1-2):70-7. PubMed ID: 20810131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Globular Glial Mixed Four Repeat Tau and TDP-43 Proteinopathy with Motor Neuron Disease and Frontotemporal Dementia.
    Takeuchi R; Toyoshima Y; Tada M; Tanaka H; Shimizu H; Shiga A; Miura T; Aoki K; Aikawa A; Ishizawa S; Ikeuchi T; Nishizawa M; Kakita A; Takahashi H
    Brain Pathol; 2016 Jan; 26(1):82-94. PubMed ID: 25787090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
    Geser F; Winton MJ; Kwong LK; Xu Y; Xie SX; Igaz LM; Garruto RM; Perl DP; Galasko D; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2008 Jan; 115(1):133-45. PubMed ID: 17713769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: a systematic neuropathological review.
    Schipper LJ; Raaphorst J; Aronica E; Baas F; de Haan R; de Visser M; Troost D
    Neuropathol Appl Neurobiol; 2016 Oct; 42(6):547-60. PubMed ID: 26373655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases.
    Mackenzie IR; Neumann M
    Acta Neuropathol; 2020 Jan; 139(1):83-98. PubMed ID: 31501924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and neuropathological features of ALS/FTD with TIA1 mutations.
    Hirsch-Reinshagen V; Pottier C; Nicholson AM; Baker M; Hsiung GR; Krieger C; Sengdy P; Boylan KB; Dickson DW; Mesulam M; Weintraub S; Bigio E; Zinman L; Keith J; Rogaeva E; Zivkovic SA; Lacomis D; Taylor JP; Rademakers R; Mackenzie IRA
    Acta Neuropathol Commun; 2017 Dec; 5(1):96. PubMed ID: 29216908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p.
    Hsiung GY; DeJesus-Hernandez M; Feldman HH; Sengdy P; Bouchard-Kerr P; Dwosh E; Butler R; Leung B; Fok A; Rutherford NJ; Baker M; Rademakers R; Mackenzie IR
    Brain; 2012 Mar; 135(Pt 3):709-22. PubMed ID: 22344582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
    Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death.
    Thal DR; Tomé SO
    Brain Res Bull; 2022 Nov; 190():204-217. PubMed ID: 36244581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers.
    Gendron TF; van Blitterswijk M; Bieniek KF; Daughrity LM; Jiang J; Rush BK; Pedraza O; Lucas JA; Murray ME; Desaro P; Robertson A; Overstreet K; Thomas CS; Crook JE; Castanedes-Casey M; Rousseau L; Josephs KA; Parisi JE; Knopman DS; Petersen RC; Boeve BF; Graff-Radford NR; Rademakers R; Lagier-Tourenne C; Edbauer D; Cleveland DW; Dickson DW; Petrucelli L; Boylan KB
    Acta Neuropathol; 2015 Oct; 130(4):559-73. PubMed ID: 26350237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unfolded protein response activation in C9orf72 frontotemporal dementia is associated with dipeptide pathology and granulovacuolar degeneration in granule cells.
    Gami-Patel P; van Dijken I; Meeter LH; Melhem S; Morrema THJ; Scheper W; van Swieten JC; Rozemuller AJM; Dijkstra AA; Hoozemans JJM
    Brain Pathol; 2021 Jan; 31(1):163-173. PubMed ID: 32865835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.
    Josephs KA; Murray ME; Tosakulwong N; Weigand SD; Serie AM; Perkerson RB; Matchett BJ; Jack CR; Knopman DS; Petersen RC; Parisi JE; Petrucelli L; Baker M; Rademakers R; Whitwell JL; Dickson DW
    Acta Neuropathol; 2019 Feb; 137(2):227-238. PubMed ID: 30604226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
    Young AL; Vogel JW; Robinson JL; McMillan CT; Ossenkoppele R; Wolk DA; Irwin DJ; Elman L; Grossman M; Lee VMY; Lee EB; Hansson O
    Brain; 2023 Jul; 146(7):2975-2988. PubMed ID: 37150879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCBP2 Is Downregulated in Degenerating Neurons and Rarely Observed in TDP-43-Positive Inclusions in Sporadic Amyotrophic Lateral Sclerosis.
    Yoshimura M; Honda H; Sasagasako N; Mori S; Hamasaki H; Suzuki SO; Ishii T; Ninomiya T; Kira JI; Iwaki T
    J Neuropathol Exp Neurol; 2021 Feb; 80(3):220-228. PubMed ID: 33313661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
    Takeda T
    Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TDP-43 in differential diagnosis of motor neuron disorders.
    Dickson DW; Josephs KA; Amador-Ortiz C
    Acta Neuropathol; 2007 Jul; 114(1):71-9. PubMed ID: 17569066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.